These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 23684417)
1. Pathogenesis of Lassa fever virus infection: I. Susceptibility of mice to recombinant Lassa Gp/LCMV chimeric virus. Lee AM; Cruite J; Welch MJ; Sullivan B; Oldstone MB Virology; 2013 Aug; 442(2):114-21. PubMed ID: 23684417 [TBL] [Abstract][Full Text] [Related]
2. An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice. Hashizume M; Takashima A; Iwasaki M J Virol; 2024 Jun; 98(6):e0057824. PubMed ID: 38767352 [TBL] [Abstract][Full Text] [Related]
3. Evolution of recombinant lymphocytic choriomeningitis virus/Lassa virus in vivo highlights the importance of the GPC cytosolic tail in viral fitness. Sommerstein R; Ramos da Palma J; Olschläger S; Bergthaler A; Barba L; Lee BP; Pasquato A; Flatz L J Virol; 2014 Aug; 88(15):8340-8. PubMed ID: 24829355 [TBL] [Abstract][Full Text] [Related]
4. Residues K465 and G467 within the Cytoplasmic Domain of GP2 Play a Critical Role in the Persistence of Lymphocytic Choriomeningitis Virus in Mice. Iwasaki M; Ng CT; Cubitt B; de la Torre JC J Virol; 2016 Nov; 90(22):10102-10112. PubMed ID: 27581982 [TBL] [Abstract][Full Text] [Related]
5. Innate and adaptive immune control of genetically engineered live-attenuated arenavirus vaccine prototypes. Pinschewer DD; Flatz L; Steinborn R; Horvath E; Fernandez M; Lutz H; Suter M; Bergthaler A Int Immunol; 2010 Sep; 22(9):749-56. PubMed ID: 20584765 [TBL] [Abstract][Full Text] [Related]
6. Lassa Virus Vaccine Candidate ML29 Generates Truncated Viral RNAs Which Contribute to Interfering Activity and Attenuation. Johnson DM; Cubitt B; Pfeffer TL; de la Torre JC; Lukashevich IS Viruses; 2021 Jan; 13(2):. PubMed ID: 33573250 [TBL] [Abstract][Full Text] [Related]
8. Effect of Strain Variations on Lassa Virus Z Protein-Mediated Human RIG-I Inhibition. Huang Q; Liu X; Brisse M; Ly H; Liang Y Viruses; 2020 Aug; 12(9):. PubMed ID: 32824946 [TBL] [Abstract][Full Text] [Related]
9. Different mechanisms of cell entry by human-pathogenic Old World and New World arenaviruses. Rojek JM; Sanchez AB; Nguyen NT; de la Torre JC; Kunz S J Virol; 2008 Aug; 82(15):7677-87. PubMed ID: 18508885 [TBL] [Abstract][Full Text] [Related]
10. A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans. Botten J; Whitton JL; Barrowman P; Sidney J; Whitmire JK; Alexander J; Kotturi MF; Sette A; Buchmeier MJ J Virol; 2010 Oct; 84(19):9947-56. PubMed ID: 20668086 [TBL] [Abstract][Full Text] [Related]
11. Role of DC-SIGN in Lassa virus entry into human dendritic cells. Goncalves AR; Moraz ML; Pasquato A; Helenius A; Lozach PY; Kunz S J Virol; 2013 Nov; 87(21):11504-15. PubMed ID: 23966408 [TBL] [Abstract][Full Text] [Related]
12. Axl Can Serve as Entry Factor for Lassa Virus Depending on the Functional Glycosylation of Dystroglycan. Fedeli C; Torriani G; Galan-Navarro C; Moraz ML; Moreno H; Gerold G; Kunz S J Virol; 2018 Mar; 92(5):. PubMed ID: 29237830 [TBL] [Abstract][Full Text] [Related]
13. Pathogenic Old World arenaviruses inhibit TLR2/Mal-dependent proinflammatory cytokines in vitro. Hayes MW; Carrion R; Nunneley J; Medvedev AE; Salvato MS; Lukashevich IS J Virol; 2012 Jul; 86(13):7216-26. PubMed ID: 22532679 [TBL] [Abstract][Full Text] [Related]
14. Severe Human Lassa Fever Is Characterized by Nonspecific T-Cell Activation and Lymphocyte Homing to Inflamed Tissues. Port JR; Wozniak DM; Oestereich L; Pallasch E; Becker-Ziaja B; Müller J; Rottstegge M; Olal C; Gómez-Medina S; Oyakhliome J; Ighodalo Y; Omomoh E; Olokor T; Adomeh DI; Asogun D; Ogbani-Emovon E; Hartmann K; Krasemann S; Nelson EV; Escudero-Pérez B; McElroy AK; Günther S; Muñoz-Fontela C J Virol; 2020 Oct; 94(21):. PubMed ID: 32817220 [TBL] [Abstract][Full Text] [Related]
15. Lassa Virus Cell Entry via Dystroglycan Involves an Unusual Pathway of Macropinocytosis. Oppliger J; Torriani G; Herrador A; Kunz S J Virol; 2016 Jul; 90(14):6412-6429. PubMed ID: 27147735 [TBL] [Abstract][Full Text] [Related]
16. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Branco LM; Grove JN; Geske FJ; Boisen ML; Muncy IJ; Magliato SA; Henderson LA; Schoepp RJ; Cashman KA; Hensley LE; Garry RF Virol J; 2010 Oct; 7():279. PubMed ID: 20961433 [TBL] [Abstract][Full Text] [Related]
17. Comprehensive Interactome Analysis Reveals that STT3B Is Required for N-Glycosylation of Lassa Virus Glycoprotein. Zhu S; Wan W; Zhang Y; Shang W; Pan X; Zhang LK; Xiao G J Virol; 2019 Dec; 93(23):. PubMed ID: 31511384 [TBL] [Abstract][Full Text] [Related]
18. Lymphocytic choriomeningitis virus (LCMV) infection of macaques: a model for Lassa fever. Zapata JC; Pauza CD; Djavani MM; Rodas JD; Moshkoff D; Bryant J; Ateh E; Garcia C; Lukashevich IS; Salvato MS Antiviral Res; 2011 Nov; 92(2):125-38. PubMed ID: 21820469 [TBL] [Abstract][Full Text] [Related]
19. Shedding of soluble glycoprotein 1 detected during acute Lassa virus infection in human subjects. Branco LM; Grove JN; Moses LM; Goba A; Fullah M; Momoh M; Schoepp RJ; Bausch DG; Garry RF Virol J; 2010 Nov; 7():306. PubMed ID: 21062490 [TBL] [Abstract][Full Text] [Related]